{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T17:12:20Z","timestamp":1793121140527,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T00:00:00Z","timestamp":1564099200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12328-019-01026-1","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T18:02:48Z","timestamp":1564164168000},"page":"1-5","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Diffuse large B-cell lymphoma of the colon and rectum in a patient with colonic Crohn\u2019s disease treated with infliximab and azathioprine"],"prefix":"10.1007","volume":"13","author":[{"given":"Koichi","family":"Sato","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1143-5021","authenticated-orcid":false,"given":"Tomoaki","family":"Suga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiichi","family":"Daikuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,26]]},"reference":[{"key":"1026_CR1","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32:3059\u201367.","journal-title":"J Clin Oncol."},{"key":"1026_CR2","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa0904492","volume":"362","author":"JF Colombel","year":"2010","unstructured":"Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn`s disease. N Engl J Med. 2010;362:1383\u201395.","journal-title":"N Engl J Med."},{"key":"1026_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.cgh.2014.07.058","volume":"13","author":"FI Scott","year":"2015","unstructured":"Scott FI, Vajravelu RK, Bewtra M, et al. The benefit-to-risk balance of combining infliximab with azathioprine varies with age: a markov model. Clin Gastroenterol Hepatol. 2015;13:302\u20139.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"1026_CR4","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.crohns.2012.04.007","volume":"7","author":"S Saito","year":"2013","unstructured":"Saito S, Shimizu U, Nan Z, et al. Economic impact of combination therapy with infliximab plus azathioprine for drug-refractory Crohn's disease: a cost-effectiveness analysis. J Crohns Colitis. 2013;7:167\u201374.","journal-title":"J Crohns Colitis."},{"key":"1026_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjv141","volume":"9","author":"V Annese","year":"2015","unstructured":"Annese V, Beaugerie L, Egan L, et al. European evidence based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015;9:1\u201321.","journal-title":"J Crohns Colitis."},{"key":"1026_CR6","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1016\/S0140-6736(09)61302-7","volume":"374","author":"L Beaugerie","year":"2009","unstructured":"Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet. 2009;374:1617\u201325.","journal-title":"Lancet"},{"key":"1026_CR7","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1038\/ajg.2011.283","volume":"106","author":"LJ Herrinton","year":"2011","unstructured":"Herrinton LJ, Liu L, Weng X, et al. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease. Am J Gastroenterol. 2011;106:2146\u201353.","journal-title":"Am J Gastroenterol."},{"key":"1026_CR8","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/ajg.2013.249","volume":"108","author":"T Jess","year":"2013","unstructured":"Jess T, Horv\u00e1th-Puh\u00f3 E, Fallingborg J, et al. Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study. Am J Gastroenterol. 2013;108:1869\u201376.","journal-title":"Am J Gastroenterol."},{"key":"1026_CR9","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1136\/gut.2004.049460","volume":"54","author":"A Kandiel","year":"2005","unstructured":"Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121\u20135.","journal-title":"Gut"},{"key":"1026_CR10","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1001\/jama.2017.16071","volume":"318","author":"M Lemaitre","year":"2017","unstructured":"Lemaitre M, Kirchgesner J, Rudnichi A, et al. Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease. JAMA. 2017;318:1679\u201386.","journal-title":"JAMA"},{"key":"1026_CR11","first-page":"350","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"P Gualard","year":"2008","unstructured":"Gualard P, Swerdlow SH, Harris NL, et al. Other iatrogenic immunodeficiency-associated lymphoproliferative disorders. In: Swerdlow SH, editor. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: International Agency for Research on Cancer; 2008. p. 350\u2013351."},{"key":"1026_CR12","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1136\/gut.2008.163279","volume":"57","author":"M Shale","year":"2008","unstructured":"Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57:1639\u201341.","journal-title":"Gut"},{"key":"1026_CR13","doi-asserted-by":"publisher","first-page":"9411","DOI":"10.3748\/wjg.v22.i42.9411","volume":"22","author":"TY Zhang","year":"2016","unstructured":"Zhang TY, Lin Y, Fan R, et al. Potential model for differential diagnosis between Crohn's disease and primary intestinal lymphoma. World J Gastroenterol. 2016;22:9411\u20138.","journal-title":"World J Gastroenterol."},{"key":"1026_CR14","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.crohns.2007.10.005","volume":"2","author":"ALS Roman","year":"2008","unstructured":"Roman ALS, Domselaar MV, Rivero M, et al. Complete remission of a primary rectal lymphoma on ulcerative colitis, after withdrawal of azathioprine and infliximab. J Crohns Colitis. 2008;2:93\u20136.","journal-title":"J Crohns Colitis."},{"key":"1026_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s12328-017-0802-8","volume":"11","author":"C Bernardes","year":"2018","unstructured":"Bernardes C, Russo P, Carvalho D, et al. Safe use of infliximab for the treatment of severe perianal Crohn\u2019s disease after diagnosis and treatment of lymphoma. Clin J Gastroenterol. 2018;11:48\u201352.","journal-title":"Clin J Gastroenterol."},{"issue":"Suppl 1","key":"1026_CR16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000367861","volume":"32","author":"D Laharie","year":"2014","unstructured":"Laharie D. Previous cancer and\/or lymphoma in patients with refractory IBD-pro: anti-TNF or immunosuppressive treatment. Dig Dis. 2014;32(Suppl 1):116\u201321.","journal-title":"Dig Dis."}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-01026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-019-01026-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-019-01026-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,24]],"date-time":"2020-07-24T23:30:23Z","timestamp":1595633423000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-019-01026-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,26]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["1026"],"URL":"https:\/\/doi.org\/10.1007\/s12328-019-01026-1","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,26]]},"assertion":[{"value":"18 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed have been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human rights"}},{"value":"Informed consent was obtained from the patient for being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}